Peng Xiao MD
Instructor, Anaesthesia, Massachusetts General Hospital, Harvard Medical
Join to View Full Profile
243 Charles StBoston, MA 02114
Phone+1 617-573-3380
Fax+1 617-573-4033
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Peng Xiao, MD is a board certified anesthesiologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, West Virginia, and Pennsylvania. He is an Instructor at Massachusetts General Hospital.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Anesthesiology, 1998 - 2001
Icahn School of Medicine at Mount Sinai (New York Eye and Ear Infirmary at Mount Sinai)Residency, Surgery, 1997 - 1998
Suzhou Medical CollegeClass of 1982
Certifications & Licensure
MA State Medical License 2001 - 2025
WV State Medical License 2001 - 2025
PA State Medical License 1999 - 2001
American Board of Anesthesiology Anesthesiology
Publications & Presentations
PubMed
- Quantitative Analysis of the Minimum Clinically Important Difference in the Brief Pain Inventory After Total Knee Arthroplasty.Shunxing Wang, Shuxin Yao, Peng Xiao, Lei Shang, Chao Xu
Journal of Pain Research. 2025-01-01 - 4 citationsA metabolic switch orchestrated by IL-18 and the cyclic dinucleotide cGAMP programs intestinal tolerance.Randall T Mertens, Aditya Misra, Peng Xiao, Seungbyn Baek, Joseph M Rone
Immunity. 2024-09-10 - The association between preoperative serum cholinesterase and all-cause mortality in geriatric patients with hip fractures: a cohort study of 2387 patients.Yan-Ning Zhang, Peng Xiao, Bin-Fei Zhang
Perioperative Medicine. 2024-07-24
Press Mentions
MBZUAI Welcomes Senior Delegation from Weizmann Institute in Abu DhabiMay 3rd, 2021- G42 and ONT Co-Develop Ultra-Scalable RNA Sequencing Based Solution for COVID-19 DetectionJune 11th, 2020
- UAE’s Group 42 and UK’s Oxford Nanopore Co-Develop Ultra-Scalable Solution for COVID-19 DetectionJune 9th, 2020
- Join now to see all
